aap makes a stable start to financial year 2025 - growth in the region with the highest sales EMEA region

EQS-News: aap Implantate AG / Key word(s): Quarterly / Interim Statement aap makes a stable start to financial year 2025 - growth in the region with the highest sales EMEA region 06.05.2025 / 12:25 CET/CEST The issuer is solely responsible for the content of this announcement. Silver: 12-month observation period runs smoothly Q1 sales show sustained growth in the business Q1 sales form a strong basis for growth in Q2 aap Implantate AG ("aap" or "Company") started the first quarter of 2025 with stable business development. Sales were on a par with the previous year. The EMEA region remained the strongest market region in terms of sales and made a significant contribution to the overall result - with growth both in the core markets and in several non-EU countries, particularly due to the successful placement of new products with US FDA approval.

Q1/2025 - Sales

Turnover in TEUR	Q1/2025	Q1/2024	Change
EMEA (= Europe, Middle East, Africa)	1.702	1.456	+17%
North America	648	731	-11%
LATAM (= Latin America)	579	788	-27%
APAC (= Asia-Pacific)	155	149	+4%
Turnover	3.084	3.124	-1%

While the first quarter of 2024 was still heavily characterized by set investments, the current result shows a structurally healthier trend: the implant business grew by around 7%, underlining the sustained demand in the core business. This positive development successfully offset the expected declines in the capital goods sector, particularly in the EMEA region.